CSL shares have dropped significantly in 2025, reaching a seven-year low, due to restructuring and downgraded growth prospects. The company’s core business is robust, with ongoing global demand and ...

CSL shares have seen a significant downturn due to recent challenges, yet analysts see potential for recovery, with a projected rebound to $275, driven by its strong foundation and global healthcare ...

The College Swimming League (CSL), a revolutionary sports enterprise, today unveiled its plans to fundamentally reimagine college swimming. Founded by Robert Kent and Kyle Sockwell, with support from ...

Forget one of one: this particular BMW 3.0 CSL is, quite literally, the very first M race car, and it’s up for sale for presumably many dollars. The very first official BMW M project was the 3.0 CSL.

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

Alongside the U.S. government’s overhaul of the federal vaccine infrastructure, influenza vaccination rates in the country have plummeted below the expectations of a key player in the space. That ...

SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of the Triangle's largest ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...